Hangzhou Biotest Biotech Co Ltd (688767) — Cash Flow-to-Debt Ratio
Hangzhou Biotest Biotech Co Ltd (688767) has a Cash Flow-to-Debt Ratio of 0.21x as of September 2025, meaning its operating cash flow of CN¥28.39 Million could theoretically repay 0% of its total liabilities (CN¥134.75 Million) in one year. See 688767 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hangzhou Biotest Biotech Co Ltd Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Hangzhou Biotest Biotech Co Ltd across 9 annual periods. For the full cash flow conversion analysis, see Hangzhou Biotest Biotech Co Ltd (688767) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Hangzhou Biotest Biotech Co Ltd (2017–2025)
Year-by-year debt coverage analysis for Hangzhou Biotest Biotech Co Ltd. Check Hangzhou Biotest Biotech Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.63x | CN¥106.47 Million | CN¥168.17 Million | ▼ -6.7% |
| 2024 | 0.68x | CN¥128.83 Million | CN¥189.79 Million | ▼ -17.9% |
| 2023 | 0.83x | CN¥131.38 Million | CN¥158.82 Million | ▼ -77.8% |
| 2022 | 3.72x | CN¥703.21 Million | CN¥188.92 Million | ▲ +32.5% |
| 2021 | 2.81x | CN¥908.12 Million | CN¥323.36 Million | ▲ +20.2% |
| 2020 | 2.34x | CN¥446.07 Million | CN¥190.89 Million | ▲ +669.3% |
| 2019 | 0.30x | CN¥25.67 Million | CN¥84.50 Million | ▼ -19.0% |
| 2018 | 0.37x | CN¥21.17 Million | CN¥56.48 Million | ▲ +153.7% |
| 2017 | 0.15x | CN¥7.07 Million | CN¥47.88 Million | — |